title: Prevention and treatment for Epstein-Barr virus infection and related cancers.
abstract: Epstein-Barr virus (EBV) was the first herpes virus described as being oncogenic in humans. EBV infection is implicated in post-transplant lymphoproliferative diseases (PTLD) and several other cancers in non-immunocompromised patients, with more than 200,000 new cases per year. While prevention of PTLD is improving, mainly based on EBV monitoring and preemptive tapering of immunosuppression, early diagnosis remains the best current option for the other malignancies. Significant progress has been achieved in treatment, with decreased mortality and morbidity, but some challenges are still to face, especially for the more aggressive diseases. Possible prevention by EBV vaccination would be a more global approach of this public health problem, but further active research is needed before this goal could be reached.
authors.affiliation: Université Catholique de Louvain, Cliniques Universitaires St-Luc, Avenue Hippocrate 10/1301, 1200, Brussels, Belgium, francoise.smets@uclouvain.be.
authors.forename: Françoise
authors.initials: F
authors.lastname: Smets
authors.forename: Etienne M
authors.initials: EM
authors.lastname: Sokal
mesh_terms: D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000517:prevention & control* / Q000821:virology; D004854:Herpesvirus 4, Human / Q000472:pathogenicity*; D006801:Humans; D009369:Neoplasms / Q000209:etiology / Q000517:prevention & control*